Non-live pentavalent vaccines after live measles vaccine may increase mortality
| Autor: | Ane Bærent Fisker, Sanne Marie Thysen |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Child mortality
Diphtheria-Tetanus-Pertussis Vaccine/administration & dosage Male medicine.medical_specialty Measles/mortality Measles Vaccine Measles Pentavalent vaccine 03 medical and health sciences Heterologous immunity 0302 clinical medicine Immunity 030225 pediatrics Internal medicine Medicine Humans 030212 general & internal medicine Prospective Studies Diphtheria-Tetanus-Pertussis Vaccine Proportional Hazards Models General Veterinary General Immunology and Microbiology business.industry Hazard ratio Public Health Environmental and Occupational Health Infant Expanded programme on immunizations medicine.disease Vaccination Infectious Diseases Live measles vaccine Immunization Molecular Medicine Female Measles Vaccine/administration & dosage business Non-specific effects of vaccines |
| Zdroj: | Fisker, A B & Thysen, S M 2018, ' Non-live pentavalent vaccines after live measles vaccine may increase mortality ', Vaccine, vol. 36, no. 41, pp. 6039-6042 . https://doi.org/10.1016/j.vaccine.2018.08.083 |
| ISSN: | 1873-2518 |
| DOI: | 10.1016/j.vaccine.2018.08.083 |
| Popis: | Live measles vaccine (MV) may have beneficial off-target/non-specific effects (NSEs) reducing child mortality beyond prevention of measles infection. In contrast, the non-live pentavalent (Diphtheria-Tetanus-Pertussis- H. influenzae Type B-Hepatitis B) vaccine has no beneficial NSEs. The NSEs are strongest for the most recent vaccine. Hence, sequence of vaccination may affect survival. In Guinea-Bissau, we followed 7094 measles-vaccinated children prospectively from first home visit after 9 months (when MV is scheduled) to 5 years of age. We compared survival by sequence of MV and third Pentavalent vaccine (Penta3; scheduled at 3½ months) in Cox proportional-hazards models. Compared with being vaccinated in-sequence (Penta3-then-MV), having received out-of-sequence Penta3-after-MV before the visit was associated with an adjusted Hazard Ratio (aHR) of 1.19 (95%CI: 0.84–1.69); Receiving missing Penta doses on the visit date tended to be associated with higher mortality (aHR = 1.87 (0.96–3.65)) while not receiving missing doses of Penta was not (aHR = 0.93 (0.57–1.54)), test for interaction p = 0.09. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect